GE Healthcare solution, billed as a 'unified approach to patient monitoring,' gains FDA clearance

GE Healthcare has received clearance from the U.S. Food and Drug Administration (FDA) for its patient monitoring platform, Carescape Canvas.

Carescape Canvas and Carescape One are part of an "adaptable ecosystem" that can scale up or scale down the monitoring of patients based on acuity. The platform is a FlexAcuity solution equipped with smart parameter technology for monitoring patients, leveraging micromodules that connect with standardized medical USB technology. Adding or disconnecting cables equipped for various configurations can enable more efficient care based on patient care needs, GE Healthcare said.

“As patient acuity and disease trends change rapidly, adaptability in the hospital setting is becoming more important,” Roland Schrewe, head of PICU at the University of Frankfurt, said in a statement. “We look for ways to improve the care experience by delivering quality clinical measurements where and when they are needed, giving care providers the information they need to make the best possible clinical decisions. GE Healthcare’s CARESCAPE Canvas provides a precise, standardized and flexible patient monitoring solution that adapts to patient needs with the ease of switching out a cable.”